MOA Life Plus
Korea - YonginBiotechnology
Focus: MOA Life Plus is a newly founded (2024) Korean biotech company headquartered in Yongin specializing in mucosal immunity medicine. The company is in early-stage development with no disclosed products or revenue.
Profile data last refreshed 3h ago · AI intelligence enriched 1mo ago
Open Jobs
5+5 this month
Growing — net +5 jobs in 30d
5 jobs added vs 0 removed. Steady team buildout.
Should You Work at MOA Life Plus?
AI assessmentMOA Life Plus is a speculative early-stage bet suitable only for risk-tolerant candidates seeking founder-level impact in mucosal immunity; insufficient data and hiring freeze signal either stealth mode or undercapitalization.
Why Work Here
- Ground-floor opportunity to build a company from inception in an emerging therapeutic area (mucosal immunity) with potential broad application
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MOA Life Plus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.